Literature DB >> 16127004

Removal of pathogenic autoantibodies by immunoadsorption.

Alon Y Hershko1, Yaakov Naparstek.   

Abstract

Autoimmune diseases result from disrupted tolerance to self-antigens and subsequent damage to tissues and organs. In several diseases, specific autoantibodies have been either proved or suspected to play a role in this process. Consequently, several strategies have been devised in an attempt to discard the destructive immunoglobulins. Currently, both nonselective and epitope-specific methods are applied in several diseases. In this review, we provide a summary of the available data on elimination of pathogenic autoantibodies and discuss the advantages and pitfalls of the different approaches.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16127004     DOI: 10.1196/annals.1361.108

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  11 in total

Review 1.  [Plasma exchange as a therapeutic option in neurological disorders].

Authors:  H C Lehmann; H P Hartung; G R Hetzel; B C Kieseier
Journal:  Nervenarzt       Date:  2007-02       Impact factor: 1.214

2.  Immunoadsorption for the treatment of narcolepsy with cataplexy.

Authors:  Alessandro Pincherle; Flavio Villani; Luigi Ferini Strambi; Maria Livia Fantini; Suela Dylgjeri; Roberto Spreafico; Carlo Antozzi
Journal:  Neurol Sci       Date:  2008-12-05       Impact factor: 3.307

3.  Removal kinetics of therapeutic apheresis.

Authors:  Roberto Reverberi; Lorenzo Reverberi
Journal:  Blood Transfus       Date:  2007-07       Impact factor: 3.443

4.  Immunoadsorption of alloantibodies onto erythroid membrane antigens encapsulated into polymeric microparticles.

Authors:  Valérie Hoffart; Philippe Maincent; Alf Lamprecht; Véronique Latger-Cannard; Véronique Regnault; Christian Merle; Valérie Jouan-Hureaux; Thomas Lecompte; Claude Vigneron; Nathalie Ubrich
Journal:  Pharm Res       Date:  2007-06-14       Impact factor: 4.200

Review 5.  The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases.

Authors:  Alina Sesarman; Gestur Vidarsson; Cassian Sitaru
Journal:  Cell Mol Life Sci       Date:  2010-03-09       Impact factor: 9.261

6.  Rapid reduction of antibodies and improvement of disease activity by immunoadsorption in Chinese patients with severe systemic lupus erythematosus.

Authors:  Jinxian Huang; Guoxiang Song; Zhihua Yin; Weizhen He; Lijun Zhang; Weihong Kong; Zhizhong Ye
Journal:  Clin Rheumatol       Date:  2016-08-03       Impact factor: 2.980

7.  Successful treatment of thromboangiitis obliterans (Buerger's disease) with immunoadsorption: results of a pilot study.

Authors:  Gert Baumann; Verena Stangl; Peter Klein-Weigel; Karl Stangl; Michael Laule; Kathrin Enke-Melzer
Journal:  Clin Res Cardiol       Date:  2011-03-05       Impact factor: 5.460

8.  Extracorporeal immunoadsorption of antibodies against the VRT-101 laminin epitope in systemic lupus erythematosus: a feasibility evaluation study.

Authors:  Alon Y Hershko; Anat Scheiman-Elazari; Suhail Aamar; Yaakov Naparstek
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

Review 9.  Maternal Anti-Fetal Brain IgG Autoantibodies and Autism Spectrum Disorder: Current Knowledge and its Implications for Potential Therapeutics.

Authors:  Elizabeth Fox-Edmiston; Judy Van de Water
Journal:  CNS Drugs       Date:  2015-09       Impact factor: 5.749

10.  Novel receptor-derived cyclopeptides to treat heart failure caused by anti-β1-adrenoceptor antibodies in a human-analogous rat model.

Authors:  Valérie Boivin; Niklas Beyersdorf; Dieter Palm; Viacheslav O Nikolaev; Angela Schlipp; Justus Müller; Doris Schmidt; Vladimir Kocoski; Thomas Kerkau; Thomas Hünig; Georg Ertl; Martin J Lohse; Roland Jahns
Journal:  PLoS One       Date:  2015-02-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.